论文部分内容阅读
目的:探讨α烯醇化酶(ENO1)在胃癌组织中的表达及其临床意义。方法:基于单细胞转录组测序结果及癌症和肿瘤基因图谱(TCGA)数据库筛选，分析胃癌组织中ENO1表达及对胃癌患者预后的影响，免疫组织化学方法验证ENO1的蛋白表达水平与临床病理特征的关系。通过生物信息学手段结合分子生物学验证，预测并证实ENO1在胃癌进程中的作用。应用R 3.6.0统计软件分析，两组间计量资料比较采用独立样本n t检验，患者生存时间分析采用Kaplan-Meier分析，相关性分析采用n Pearson相关系数，以n P<0.05为差异有统计学意义。n 结果:ENO1在胃癌中表达高于正常组织(8.85±0.42比7.94±0.95，n P<0.05)，且其表达水平与肿瘤分级呈正相关。机制方面，ENO1与缺氧诱导因子-1α(HIF-1α)形成正反馈环路，两者共同促进胃癌恶性进展。此外，胃癌组织中ENO1高表达患者预后不佳(n HR＝1.64，n P<0.05)。n 结论:ENO1可能是与胃癌发生发展相关的新分子标志物。“,”Objective:To explore the expression and clinical significance of α-enolase (ENO1) in gastric cancer.Methods:Based on single-cell transcription sequencing results and the cancer genome atlas (TCGA) large data screening, the expression of ENO1 in gastric cancer tissues and its impact on the prognosis of gastric cancer patients were analyzed. Immunohistochemistry was used to verify the protein expression level of ENO1 and its relationship with clinicopathological characteristics. Bioinformatics combined with Western blotting technology was used to predict and confirm the role of ENO1 in the process of gastric cancer [hazard ratio (n HR)=1.64, n P<0.05].n Results:The expression of ENO1 in gastric cancer tissues was significantly higher than that in normal tissues (8.85±0.42 vs. 7.94±0.95, n P<0.05), and was positively correlated with tumor histologic grade (7.40±0.76 vs. 7.15±0.46,n P<0.05). ENO1 was closely related to hypoxia inducible factor (HIF)-1α. ENO1 and HIF-1α could form a positive feedback loop to promote the malignant progress of gastric cancer. In GC patients, the ENO1 expression was usually associated with poor prognosis (HR = 1.64,n P<0.05).n Conclusion:The expression of ENO1 may be a new molecular marker related to the occurrence and development of gastric cancer.